Plasma lipids during chronic antihypertensive therapy with different beta-blockers

Area of Science:

• Cardiology
• Pharmacology
• Lipid Metabolism

Background:

• Essential hypertension management often involves beta-blockers.
• Long-term effects of different beta-blockers on plasma lipids require detailed comparison.
• Understanding these effects is crucial for cardiovascular risk assessment.

Purpose of the Study:

• To compare the long-term effects of five distinct beta-blockers on plasma lipid profiles in patients with essential hypertension.
• To evaluate the impact of monotherapy with propranolol, atenolol, bisoprolol, mepindolol, and celiprolol on lipid parameters.

Main Methods:

• A 2-year randomized study involving 99 male patients with mild to moderate hypertension.
• Patients received monotherapy with one of five beta-blockers after a placebo period.
• Plasma lipids (TC, LDL-C, TG, HDL-C) and blood pressure were monitored every six months.

Main Results:

• All beta-blockers effectively reduced blood pressure.
• No significant changes in total cholesterol or LDL-cholesterol were observed with any agent.
• Propranolol and atenolol showed adverse effects on triglycerides and HDL-cholesterol, while bisoprolol and mepindolol increased triglycerides.
• Celiprolol demonstrated beneficial effects, reducing triglycerides and increasing HDL-cholesterol.

Conclusions:

• Beta-blocker choice significantly influences plasma lipid profiles in hypertensive patients.
• Celiprolol, a cardioselective beta-blocker with partial agonism, offers a favorable lipid profile compared to other agents.
• This suggests celiprolol may be a preferred option for hypertensive patients with dyslipidemia concerns.